Celgene (NASDAQ: CELG) and SCYNEXIS (NASDAQ:SCYX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Risk and Volatility
Celgene has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.
Earnings & Valuation
This table compares Celgene and SCYNEXIS’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Celgene has higher revenue and earnings than SCYNEXIS.
This is a breakdown of current ratings for Celgene and SCYNEXIS, as provided by MarketBeat.
||Strong Buy Ratings
Celgene presently has a consensus price target of $131.21, suggesting a potential upside of 23.78%. SCYNEXIS has a consensus price target of $9.50, suggesting a potential upside of 405.32%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Celgene.
This table compares Celgene and SCYNEXIS’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider & Institutional Ownership
79.7% of Celgene shares are owned by institutional investors. Comparatively, 30.9% of SCYNEXIS shares are owned by institutional investors. 1.0% of Celgene shares are owned by insiders. Comparatively, 4.0% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Celgene beats SCYNEXIS on 8 of the 12 factors compared between the two stocks.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.